Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.67 Insider Own41.16% Shs Outstand13.10M Perf Week25.87%
Market Cap54.70M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float8.07M Perf Month-18.90%
Income-8.88M PEG- EPS next Q- Inst Own3.49% Short Float1.24% Perf Quarter46.15%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio0.15 Perf Half Y-30.85%
Book/sh1.16 P/B3.44 EPS next Y- ROA-98.52% Short Interest0.10M Perf Year-
Cash/sh1.14 P/C3.50 EPS next 5Y- ROE-151.79% 52W Range2.01 - 11.44 Perf YTD-53.44%
Dividend Est.- P/FCF- EPS past 5Y- ROI-55.29% 52W High-65.12% Beta-
Dividend TTM- Quick Ratio22.98 Sales past 5Y0.00% Gross Margin- 52W Low98.50% ATR (14)0.47
Dividend Ex-Date- Current Ratio22.98 EPS Y/Y TTM-3.56% Oper. Margin0.00% RSI (14)51.86 Volatility11.52% 12.60%
Employees16 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price12.00
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q-25.39% Payout- Rel Volume0.15 Prev Close3.70
Sales Surprise- EPS Surprise-88.89% Sales Q/Q- EarningsNov 13 BMO Avg Volume644.52K Price3.99
SMA2012.74% SMA50-21.53% SMA200-17.58% Trades Volume94,963 Change7.84%
Feb-21-24 08:01AM
Jan-03-24 08:01AM
Dec-12-23 08:01AM
Dec-08-23 11:12AM
08:01AM Loading…
Dec-01-23 08:01AM
Nov-13-23 08:01AM
Nov-02-23 07:01AM
Sep-07-23 08:01AM
Sep-05-23 08:01AM
Aug-14-23 07:01AM
Aug-07-23 07:01AM
Jul-31-23 04:05PM
Jul-10-23 08:00AM
Jul-05-23 04:15PM
08:00PM Loading…
Jun-29-23 08:00PM
Intensity Therapeutics, Inc. engages in the operation a biotechnology company which develops novel immune-based therapeutic products for cancer treatment. Its product INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Westport, CT.